Trial Profile
Influences of anticoagulant treatment (RIbaroxaban vs warfarin) on Systemic inflammative markers in patients with Heart Failure and atrial fibrillation
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 04 Oct 2017
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary) ; Warfarin (Primary)
- Indications Embolism and thrombosis
- Focus Biomarker; Pharmacodynamics
- Acronyms IRIS-HF
- 30 May 2016 New trial record